Skip to main content

Market Overview

Recap: Reata Pharmaceuticals Q4 Earnings



Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q4 results.

Quarterly Results

Earnings per share increased 21.38% over the past year to ($1.25), which beat the estimate of ($2.16).

Revenue of $3,192,000 rose by 19.46% year over year, which beat the estimate of $1,440,000.

Looking Ahead

Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Mar 01, 2021

Time: 08:30 AM

ET Webcast URL:


52-week high: $209.91

52-week low: $88.17

Price action over last quarter: down 33.78%

Company Profile

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.


Related Articles (RETA)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at